INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 410m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN10m ago
Public company

ENTAENANTA PHARMACEUTICALS INC

CIK 0001177648

EDGAR filingsOpen in network
Disclosed transactions50
Buys / sells0 / 9
Max Insider Score40
Connections15with evidence

ENTA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$20K
1,467 sh
Aug 8, 2026Aug 10, 2026
traded Aug 8, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Peterson KristineDirector · Mar 13, 2026
  • ← Insider ofevidence
    Hata Yujiro SDirector · Mar 13, 2026
  • ← Insider ofevidence
    Russell LesleyDirector · Mar 13, 2026
9
HS
Hata Yujiro SDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A
—
20.0K sh
Mar 11, 2026
Mar 13, 2026
traded Mar 11, 2026
+2d
SEC FORM 4

Evidence

9
FG
Foletta Mark GDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

9
RL
Russell LesleyDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

9
VT
Vance TerryDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

9
CA
Carter Bruce L ADirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

9
PK
Peterson KristineDirector
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
20.0K sh
Mar 11, 2026Mar 13, 2026
traded Mar 11, 2026
+2dSEC FORM 4

Evidence

5
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
4,800 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,650 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

13
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
5,225 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$49K
3,413 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

21
KP
Kowalsky Matthew PaulChief Legal Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
4,175 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
KP
Kowalsky Matthew PaulChief Legal Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,318 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

21
KP
Kowalsky Matthew PaulChief Legal Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$27K
1,902 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

5
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,575 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
4,987 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$46K
3,257 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,575 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
4,987 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
1,650 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
5,225 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

5
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$49K
3,413 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

5
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
15.2K sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

8
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$88K
6,155 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

9
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$46K
3,257 sh
Feb 12, 2026Feb 13, 2026
traded Feb 12, 2026
+1dSEC FORM 4

Evidence

40
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$30K
2,106 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

36
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$20K
1,394 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

39
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$67K
4,743 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

36
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$34K
2,390 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

32
CS
Capps Kathleen S.See Remarks
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$4,596
323 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

36
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$11K
798 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

32
TR
Trout Harry R. IIISee Remarks
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$7,713
542 sh
Dec 5, 2025Dec 5, 2025
traded Dec 5, 2025
+0dSEC FORM 4

Evidence

9
TR
Trout Harry R. IIISee Remarks
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$1,483
105 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$11K
753 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$11K
753 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$27K
1,885 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

36
CS
Capps Kathleen S.See Remarks
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$2,890
207 sh
Dec 2, 2025Dec 3, 2025
traded Dec 2, 2025
+1dSEC FORM 4

Evidence

9
CS
Capps Kathleen S.See Remarks
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$1,200
85 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

9
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Tax withholding
F$7,032
498 sh
Dec 1, 2025Dec 3, 2025
traded Dec 1, 2025
+2dSEC FORM 4

Evidence

36
TR
Trout Harry R. IIISee Remarks
ENTAENANTA PHARMACEUTICALS INC
Open-market sale
SELL$5,305
380 sh
Dec 2, 2025Dec 3, 2025
traded Dec 2, 2025
+1dSEC FORM 4

Evidence

9
KL
Kieffer Tara LynnChief Product Strategy Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
100.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
KP
Kowalsky Matthew PaulChief Legal Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
90.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
RT
Rottinghaus Scott T.Chief Medical Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
110.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
OS
Or Yat SunChief Scientific Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
110.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
LR
Luly Jay R.Director, President and CEO
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
310.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

21
CS
Capps Kathleen S.See Remarks
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
3,163 sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
CS
Capps Kathleen S.See Remarks
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
6,325 sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

21
TR
Trout Harry R. IIISee Remarks
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
6,463 sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
TR
Trout Harry R. IIISee Remarks
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
12.9K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

9
LB
Luu BrendanChief Business Officer
ENTAENANTA PHARMACEUTICALS INC
Grant or award
A—
90.0K sh
Nov 25, 2025Nov 26, 2025
traded Nov 25, 2025
+1dSEC FORM 4

Evidence

← Insider ofevidence
Carter Bruce L A
Director · Mar 13, 2026
  • ← Insider ofevidence
    Vance TerryDirector · Mar 13, 2026
  • ← Insider ofevidence
    Foletta Mark GDirector · Mar 13, 2026
  • ← Insider ofevidence
    Trout Harry R. IIISee Remarks · Nov 26, 2025
  • ← Insider ofevidence
    Luu BrendanChief Business Officer · Nov 26, 2025
  • ← Insider ofevidence
    Rottinghaus Scott T.Chief Medical Officer · Nov 26, 2025
  • ← Insider ofevidence
    Kieffer Tara LynnChief Product Strategy Officer · Nov 26, 2025
  • ← Insider ofevidence
    Kowalsky Matthew PaulChief Legal Officer · Nov 26, 2025
  • ← Insider ofevidence
    Or Yat SunChief Scientific Officer · Nov 26, 2025
  • ← Insider ofevidence
    Luly Jay R.Director, President and CEO · Nov 26, 2025
  • ← Insider ofevidence
    Capps Kathleen S.See Remarks · Nov 26, 2025